Media stories about SurModics (NASDAQ:SRDX) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. SurModics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.9423842538025 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Here’s Why You Should Invest in Surmodics (SRDX) Right Now (finance.yahoo.com)
- Here's Why You Should Invest in Surmodics (SRDX) Right Now (finance.yahoo.com)
- SurModics (SRDX) Upgraded to “Buy” by ValuEngine (americanbankingnews.com)
- Can The Uptrend Continue for Surmodics (SRDX)? (finance.yahoo.com)
Several analysts have issued reports on SRDX shares. BidaskClub lowered shares of SurModics from a “hold” rating to a “sell” rating in a research report on Tuesday, December 12th. Zacks Investment Research upgraded shares of SurModics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Needham & Company LLC started coverage on shares of SurModics in a research report on Tuesday, February 27th. They issued a “buy” rating and a $42.00 price target on the stock. Lake Street Capital restated a “buy” rating and issued a $38.00 price target (up from $35.00) on shares of SurModics in a research report on Wednesday, February 28th. Finally, Barrington Research upgraded shares of SurModics from a “market perform” rating to an “outperform” rating in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $37.00.
SurModics (NASDAQ:SRDX) last issued its earnings results on Thursday, February 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.15. SurModics had a net margin of 0.10% and a return on equity of 5.04%. The business had revenue of $17.01 million for the quarter, compared to analyst estimates of $17.69 million. sell-side analysts predict that SurModics will post -0.05 earnings per share for the current year.
In other news, VP Joseph J. Stich sold 1,000 shares of SurModics stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $33.53, for a total transaction of $33,530.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.70% of the stock is currently owned by insiders.
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.